Regulus Therapeutics Inc.: key financial figures for fiscal year 2024 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:
- Net Income/Loss (FY2024)
- -$46.4M
- Total Assets (FY2024)
- $84.2M
- Total Equity (FY2024)
- $76.4M
- Cash Flows from Operating Activities (FY2024)
- -$41.7M
Source: Regulus Therapeutics Inc. 10-K filing (FY2024). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.
